What is Tofacitinib?
Tofacitinib is an oral small molecule kinase inhibitor that selectively inhibits Janus kinase (JAK) enzymes, which play a key role in signaling pathways leading to inflammation and immune response. It is used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ulcerative colitis.
When did Tofacitinib become available on the market?
Tofacitinib was first approved by the US FDA in November 2012 for the treatment of moderate to severe rheumatoid arthritis in adults who responded inadequately to disease-modifying antirheumatic drugs (DMARDs), methotrexate, or tumor necrosis factor (TNF) inhibitors.
What is the current market status of Tofacitinib?
According to a report by Statista, the global tofacitinib market size was valued at approximately $13.4 billion in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 13.6% from 2020 to 2027 [1].
Who manufactures Tofacitinib?
Tofacitinib is developed by Pfizer and is marketed under the brand name Xeljanz. Pfizer holds the exclusive rights to market tofacitinib in the global market, including the United States, Europe, and Japan.
What are the competing products in the market?
Other JAK inhibitors, such as baricitinib (Olumiant) and filgotinib (Jyseleca), also compete with tofacitinib in the treatment of rheumatoid arthritis and other autoimmune diseases.
What are the patents for Tofacitinib?
According to DrugPatentWatch.com, Pfizer's US and EU patents for tofacitinib are scheduled to expire in 2033 and 2034, respectively [2]. After patent expiration, biosimilars can enter the market, potentially competing with the original product.
What are the side effects of Tofacitinib?
Common side effects of tofacitinib include upper respiratory tract infections, infections, stomach problems, blood and lymphatic system problems, and nervous system problems, such as dizziness and headaches. Patients taking tofacitinib should be closely monitored for signs of infection, including fever, chills, or other flu-like symptoms.
References:
[1] Statista. (2021). Global tofacitinib market size 2020-2027.
[2] DrugPatentWatch.com. (2023). Tofacitinib (Xeljanz) patents and regulatory history.
Sources:
* Statista. (2021). Global tofacitinib market size 2020-2027.
* DrugPatentWatch.com. (2023). Tofacitinib (Xeljanz) patents and regulatory history.
* Pfizer. (2023). Xeljanz (Tofacitinib Citrate) Prescribing Information.